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OBJECTIVES We sought to determine whether disturbances of myocardial contractility and reflectivity
could be detected in diabetic patients without overt heart disease and whether these changes
were independent and incremental to left ventricular hypertrophy (LVH).
BACKGROUND Left ventricular (LV) dysfunction is associated with diabetes mellitus, but LVH is common
in this population and the relationship between diabetic LV dysfunction and LVH is unclear.
METHODS We studied 186 patients with normal ejection fraction and no evidence of CAD: 48 with
diabetes mellitus only (DM group), 45 with LVH only (LVH group), 45 with both diabetes
and LVH (DH group), and 48 normal controls. Peak strain and strain rate of six walls in
apical four-chamber, long-axis, and two-chamber views were evaluated and averaged for each
patient. Calibrated integrated backscatter (IB) was assessed by comparison of the septal or
posterior wall with pericardial IB intensity.
RESULTS All patient groups (DM, DH, LVH) showed reduced systolic function compared with
controls, evidenced by lower peak strain (p  0.001) and strain rate (p  0.005). Calibrated
IB, signifying myocardial reflectivity, was greater in each patient group than in controls (p 
0.05). Peak strain and strain rate were significantly lower in the DH group than in those in
the DM alone (p  0.03) or LVH alone (p  0.01) groups.
CONCLUSIONS Diabetic patients without overt heart disease demonstrate evidence of systolic dysfunction and
increased myocardial reflectivity. Although these changes are similar to those caused by LVH,
they are independent and incremental to the effects of LVH. (J Am Coll Cardiol 2003;41:
611–7) © 2003 by the American College of Cardiology Foundation
Diabetes mellitus is associated with heart failure (1), largely
through its association with hypertension and coronary
artery disease (CAD). However, the presence of primary
myocardial disease in diabetic patients has been anticipated
from evidence of systolic and diastolic left ventricular (LV)
dysfunction, even in the absence of other known cardiac
disease (2–5). Interstitial fibrosis has been documented in
biopsy studies of diabetic patients without hypertension or
CAD (2,6), and changes due to fibrosis have been docu-
mented noninvasively with echocardiography. In less se-
lected patients (without excluding contributions from hy-
pertrophy and coronary disease), calibrated integrated
backscatter (IB) (a marker of myocardial reflectivity), have
been shown to be abnormal in the hearts of diabetic subjects
(7,8). Myocardial strain and strain rate are new markers that
may be used to measure regional myocardial function
(9–12), but they have not been applied in diabetic subjects.
Left ventricular hypertrophy (LVH) and hypertension are
common comorbidities of diabetes mellitus. Indeed, the
combination of diabetes and hypertension is particularly
damaging to the heart, and drug studies have shown a
significant effect of small increments of blood pressure
control in diabetic populations (13). We sought to deter-
mine whether the recorded changes in the diabetic heart
were independent of LVH, after excluding a significant
contribution from CAD. This study used sensitive markers
of systolic performance and myocardial reflectivity to inves-
tigate early myocardial changes in patients with diabetes and
normal systolic function in diabetic patients with and
without LVH.
METHODS
Subjects. We studied 186 subjects (93 with and 93 without
diabetes mellitus) who were eligible for recruitment if they
had an ejection fraction 50% as assessed by the modified
biplane Simpson’s method, no history of CAD, and a
normal stress echocardiogram and/or coronary angiogram.
We excluded patients with abnormal systolic function,
moderate-to-severe valvular disease, CAD, atrial fibrillation
or other severe arrhythmias, and congenital heart disease.
The 186 subjects were divided into four groups: 48 with
diabetes mellitus only (DM group; 33 male, 15 female,
mean age 60  10 years); 45 with both diabetes and LVH
(DH group; 16 male, 29 female, mean age 59  13 years);
45 with LVH only (LVH group; 22 male, 23 female, mean
age 62  12 years); and 48 normal controls (control group;
25 male, 23 female, mean age 58  10 years).
Acquisition. Using a standard commercial ultrasound ma-
chine (Vivid 5, GE Vingmed, Horten, Norway) with a
2.5-MHz phased array probe, we acquired three apical
views (apical four-chamber, two-chamber, and long-axis
views) in gray scale and color tissue Doppler modes. Mitral
inflow velocities were recorded by using conventional
pulsed-wave Doppler echocardiography, in the usual fash-
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ion. All images were saved digitally in raw-data format to
magneto optical disk for offline analysis.
Echocardiographic data analysis. Left ventricular diame-
ters and wall thicknesses were measured from two-
dimensional targeted M-mode echocardiography, using the
criteria of the American Society of Echocardiography (14).
Fractional shortening was calculated using the standard
formula (15), and LV mass was determined by Devereux’s
formula (16). Left ventricular hypertrophy was defined as
LV mass index (g/m2) 131 g/m2 in men and 100 g/m2
in women (17). Resting LV end-diastolic, end-systolic
volumes and ejection fraction were computed using a
modified Simpson’s biplane method. Each representative
value was obtained from the average of three measurements.
Strain and strain rate data analysis. Tissue velocity curves
were obtained from color tissue Doppler images using a
computer (Apple Macintosh G4, Cupertino, California)
and standard commercial software (Echopac, GE Ving-
med). Peak myocardial early diastolic velocity (Em) and
peak myocardial late diastolic velocity (Am) and their ratio
were obtained by placing a tissue Doppler sample volume at
the septal annulus in the apical four-chamber view.
Myocardial strain is a fundamental quality of tissue that
reflects its ability to shorten. Strain and strain rate curves
were extracted from an average of three cycles of tissue
Doppler imaging data, using an IBM computer and devel-
opmental software (Formtest V6.1, GE Vingmed). Strain
and strain rate were derived from strain and strain rate
curves obtained by placing sample bar (12 mm) on six walls
in the three apical views (18,19). Sampling in the midmyo-
cardial layer was performed in each segment and maintained
at the same position during the cardiac cycle by manually
tracking wall motion, but data were excluded if we were
unable to obtain a smooth strain curve or the angle between
the scan-line and wall was 20°. Peak strain was defined as
the greatest value on the strain curve.
Peak strain (26  4% in controls) is a measure of tissue
distortion and a marker of regional systolic function, which
has been demonstrated to be able to quantify LV function in
acute myocardial infarction (20). Peak strain rate (1.6 
0.3 s1 in controls) is an index of the speed of contraction
and can be estimated as the spatial derivative of velocities. It
is an elegant noninvasive indicator of LV contractility and
has been validated in dogs by comparison with peak elas-
tance, a gold standard of LV contractility (21).
Calibrated IB. Calibrated IB was obtained by comparison
of the septal or posterior wall IB intensity with pericardial
IB intensity in the parasternal long-axis view. The IB curve
for the septum, posterior wall or pericardium was extracted
using a computer (Apple Macintosh G4) and standard
commercial software (Echopac, GE Vingmed). Measure-
ments were obtained by placing a 9 9 pixel sample volume
in the basal septum, posterior wall or pericardium in
end-diastole. The position of the sample volume was
checked and adjusted in each frame to keep the sample
volume within the same region during the whole cardiac
cycle. Calibrated IB was obtained by subtracting average
pericardial IB intensity from average myocardial IB inten-
sity of the septum or posterior wall.
Interobserver and intraobserver variability. Variability in
the measurement of peak strain, strain rate, and calibrated
IB from a single acquisition was evaluated in 30 subjects (8
from DM group, 8 from DH group, 7 from LVH group and
7 controls) randomly selected from the 186 subjects by two
independent observers for interobserver and intraobserver
variability. To determine reproducibility, the same observer
who was blinded to the former results measured peak strain,
strain rate and calibrated IB for each of the selected patients
again at a separate time (at least two weeks later). To test
interobserver variability, another observer (unaware of pa-
tient identity and first observer’s results) analyzed the same
patients’ data in the same way.
Statistical analysis. Values were expressed as a mean 
standard deviation. One-way analysis of variance
(ANOVA) with post-hoc test by Bonferroni was used to
examine differences among groups. Student’s independent-
samples t test was used to compare the difference between
two groups. Data were analyzed using standard statistical
software (SPSS Inc., Chicago, Illinois). A p value of 0.05
was considered statistically significant.
RESULTS
Clinical and echocardiographic characteristics. Table 1
summarizes the clinical characteristics of the four groups.
One-way ANOVA with post-hoc test by Bonferroni
showed they had comparable mean ages, heart rates, body
weights, smoking histories, and LV systolic and diastolic
functions. Patients from the DM group showed a greater
prevalence of obesity and hypercholesterolemia than con-
trols, and those with LVH had greater systolic and diastolic
blood pressure and LV dimensions and mass than controls.
In all patient groups (DM, DH, LVH), Em (5.0  2.4
cm/s; 4.7  1.9 cm/s; 5.6  1.5 cm/s, respectively) and Am
(6.4  2.2 cm/s; 6.5  1.7 cm/s; 7.1  1.2 cm/s,
Abbreviations and Acronyms
Am  peak myocardial late diastolic velocity
ANOVA  analysis of variance
CAD  coronary artery disease
DH group  diabetic patients with left ventricular
hypertrophy
DM group  diabetic patients without left ventricular
hypertrophy
Em  peak myocardial early diastolic velocity
HbA1c  hemoglobin A1c
IB  integrated backscatter
LV  left ventricular
LVH  left ventricular hypertrophy
LVH group  nondiabetic patients with left ventricular
hypertrophy
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respectively) were less than in controls (7.0  2.1 cm/s for
Em, 7.7  1.6 cm/s for Am).
There were no significant differences in diabetic duration,
types and complications, hemoglobin A1c (HbA1c), blood
glucose, lipid profile (except low-density lipoprotein choles-
terol), and treatments between DM and DH groups, but
creatinine, urea, and low-density lipoprotein cholesterol
were significantly greater in the DH group than in the DM
group (Table 2). Indices of diabetic control (HbA1c or blood
glucose) were not correlated with myocardial function (peak
strain, strain rate), or reflectivity (calibrated IB). There were
no significant differences in peak strain, strain rate, and
calibrated IB in subgroups of patients with or without
complications (e.g., nephropathy, retinopathy, and neurop-
athy). These parameters did not differ according to treat-
ment with and without angiotensin-converting enzyme
inhibitors or between patients treated with insulin or oral
hypoglycemic drugs.
Comparison of myocardial changes in the DM group,
LVH group, or both groups. The results analyzed by
one-way ANOVA with post-hoc test by Bonferroni in peak
strain, strain rate, and calibrated IB for the four groups are
shown in Figure 1. All three patient groups (DM, DH, and
LVH) showed significant decreases in peak strain compared
with controls (24  3%, 22  3%, 24  3%, all p values 
0.001). Peak strain was significantly less in the DH group
than in the DM group (p 0.03) and the LVH group (p
0.02). Strain rate was greater in controls (1.6  0.3 s1)
than in DM (1.4 0.3 s1, p 0.006), DH (1.3 0.2 s1,
p  0.001), and LVH (1.4  0.2 s1; p  0.005) groups.
Moreover, peak strain rate in the DH group was signifi-
cantly less than in the DM alone (p  0.01) or LVH (p 
0.01) groups.
Calibrated IB in the septum (22.6 6.6 dB in controls)
and posterior wall (29.0  6.2 dB) is a marker of
myocardial reflectivity. With the exception of the results in
the posterior wall of the DM group, the three patient groups
(DM, DH, LVH) showed significant increases in calibrated
IB both in the septum (18.6  7.9 dB, 17.1  7.0 dB,
17.2  6.4 dB; p  0.045, 0.001, 0.001, respectively) and
in the posterior wall (27.0  7.0 dB, 23.8  7.6 dB,
25.0 7.7 dB; p 1.0, 0.004, 0.046, respectively). There
were no significant differences in the septal or posterior wall
calibrated IB among the three patient groups.
Interobserver and intraobserver variability. There were
no significant differences in peak strain (24.1  2.8%),
strain rate (1.5  0.2 s1), and calibrated IB of the septum
(19.4  7.6 dB) and posterior wall (27.4  7.3 dB)
when these were measured by another observer (23.6 
3.3%, 1.4  0.2 s1, 19.7  6.4 dB, 26.2  5.8 dB,
respectively) or remeasured by the same observer (24.0 
3.3%, 1.4  0.2 s1, 19.1  7.4 dB, 26.2  5.8 dB,
Table 1. Clinical and echocardiographic characteristics in each group
DM Group
(n  48)
DH Group
(n  45)
LVH Group
(n  45)
Control Group
(n  48)
Age (yrs) 60  10 59  13 62  12 58  10
Heart rate (beats/min) 74  13 79  16 75  13 74  14
Systolic BP (mm Hg) 142  28 (47) 155  21 (43)* 151  21 (45)* 134  20 (48)
Diastolic BP (mm Hg) 75  14 (47) 82  14 (43)* 82  13 (45)* 73  12 (48)
Weight (kg) 90  20* 75  15# 83  15 76  17
Body mass index (kg/m2) 31  7* 28  5 29  4 27  5
Hypertension 32/48 (67%)‡ 38/45 (84%)* 44/45 (98%)* 28/48 (58%)
Hypercholesterolemia 31/47 (66%)‡ 27/44 (61%) 17/45 (38%) 16/41 (39%)
Smoker 11/47 (23%) 12/44 (27%) 13/43 (30%) 12/41 (29%)
LVDD (cm) 4.6  0.5‡ 4.7  0.5 4.9  0.5* 4.5  0.4
IVSD (cm) 1.1  0.2‡ 1.3  0.3* 1.3  0.2* 1.0  0.2
PWD (cm) 1.0  0.1‡ 1.2  0.2* 1.3  0.2a 0.9  0.2
LVFS (%) 29.0  4.4 29.4  4.4 29.6  3.8 29.6  3.9
LVMI (g/m2) 95  20‡ 154  42* 162  41* 90  19
LVEDV (ml) 90  21 89  32 95  29* 79  21
LVESV (ml) 36  15 34  16 35  13 29  9
LVEF (%) 63  6 62  7 63  7 63  7
E (m/s) 0.84  0.21(38) 0.87  0.23 (38) 0.80  0.20 (39) 0.80  0.22 (43)
A (m/s) 0.82  0.27(38) 0.92  0.28(38) 0.86  0.27(39) 0.77  0.29(43)
E/A  1 20/38 (53%) 25/38 (66%) 22/39 (56%) 20/43 (47%)
Deceleration time (ms) 258  55(37) 228  55(37) 233  58(36) 226  56(40)
Em (cm/s) 5.0  2.4 (45)* 4.7  1.9 (44)* 5.6  1.5 (44)* 7.0  2.1 (47)
Am (cm/s) 6.4  2.2 (45)* 6.5  1.7 (44)* 7.1  1.2 (44) 7.7  1.6 (47)
Em/Am  1 35/45 (78%) 36/44 (82%) 35/44 (80%) 28/47 (60%)
*Significant difference vs. controls; †significant difference between DM and DH groups; ‡significant difference between DM and LVH groups
Amitral late peak velocity; Ammyocardial late peak velocity; BP blood pressure; DH group diabetic patients with left ventricular hypertrophy; DM group diabetic
patients without left ventricular hypertrophy; DT  mitral valve deceleration time; E  mitral early peak velocity; E/A  ratio of the early to the late peak diastolic transmitral
flow velocity; Em  myocardial early peak velocity; Em/Am  ratio of the early to the late peak diastolic velocity; IVSD  end-diastolic septal thickness; LV  left ventricular;
LVDD  left ventricular end-diastolic dimension; LVEDV  left ventricular end-diastolic volume; LVESV  LV end-systolic volume; LVEF  left ventricular ejection
fraction; LVFS  LV fractional shortening; LVH group  patients with left ventricular hypertrophy; LVMI  left ventricular mass index; PWD  end-diastolic posterior wall
thickness.
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respectively). Mean absolute differences in peak strain,
strain rate, calibrated IB of the septum and posterior wall
were 1.6 1.2% (range 0.1% to 4.6%), 0.1 0.1 s1 (range
0 to 0.3 s1), 3.1  2.8 (range 0.3 dB to 9.5 dB), and
3.2  2.7 (range 0.1 dB to 9.7 dB) between the two
measurements by the same observer and were 1.8  1.2%
(range 0 to 4.3%), 0.1 0.1 s1 (range 0.0 to 0.3 s1),3.3
 2.7 dB (range 0.2 dB to 9.3 dB), 3.7  2.7 dB
(range 0.1 dB to 10.0 dB) between the two observers.
DISCUSSION
Diabetic myocardial changes may be due to metabolic
derangements (22), microvascular disease (23), and myocar-
dial fibrosis (24). The most prominent histopathologic
findings in diabetic patients without CAD and hypertension
are myocellular hypertrophy and myocardial fibrosis (25),
implying changes in both myocardial function and structure.
As hypertension and LVH frequently coexist with diabetes,
we sought in this study to compare myocardial functional
and structural changes in diabetic patients with or without
LVH with those in nondiabetic subjects with or without
LVH, in order to identify the role of diabetes alone in
relation to myocardial dysfunction, after exclusion of pa-
tients with significant coronary disease as defined by stress
echocardiography.
Reduction in myocardial contractility. A number of plau-
sible explanations have been proposed to account for re-
duced myocardial contractility in diabetes. Chronic abnor-
malities in myocardial carbohydrate and lipid metabolism
due to insulin deficiency may result in reduced adenosine
triphosphatase activity, decreased ability of the sarcoplasmic
reticulum to take up calcium (26) and an intracellular
accumulation of toxic fatty acid intermediates (22). These in
turn may lead to adenosine triphosphate depletion, changes
in calcium homeostasis and increased myocardial oxygen
consumption, and may produce a focal, progressive loss of
myofibrils, transverse tubules and sarcoplasmic reticulum,
and separation of the fasciae adherens at the intercalated
disk within myocytes (27), causing myocyte hypertrophy,
loss and replacement of fibrosis, and resulting in deleterious
effects on myocardial contractility.
Despite epidemiologic observations of the greater fre-
quency of heart failure in diabetic subjects, and credible
explanations for LV dysfunction, some studies in diabetic
patients without overt evidence of heart disease have dem-
onstrated normal contraction at rest. In these circumstances,
the contractile response during exercise was abnormal (28),
suggesting loss of contractile reserve in the early phase of
diabetic heart disease. In this situation, resting changes may
be too subtle to be identified with load-dependent indica-
tors, such as ejection fraction, and require the application of
Table 2. Clinical characteristics of diabetic patients.
DM Group DH Group p Value
Diabetes history
Duration (yrs) 11  11 (n  33) 14  10 (n  30) NS
Type (I/II) 5/43 5/40 NS
Diabetes complications
Stroke 4/48 (8%) 5/45 (11%) NS
Peripheral vascular disease 10/48 (21%) 6/45 (13%) NS
Renal impairment 9/48 (19%) 15/45 (33%) NS
Retinopathy 14/48 (29%) 12/45 (27%) NS
Neuropathy 13/48 (27%) 10/45 (22%) NS
Blood biochemistry
HbA1c (%) 7.4  1.8 7.9  1.8 NS
Glucose (mmol/l) 9.9  4.6 9.6  5.2 NS
Creatinine (mol/l) 0.11  0.06 0.23  0.25 0.002
Urea (mmol/l) 7.9  3.9 11.4  7.4 0.006
Lipid profile
Total cholesterol (mmol/l) 4.7  1.1 5.2  1.3 NS
LDL cholesterol (mmol/l) 2.4  1.0 3.1  0.9 0.019
HDL cholesterol (mmol/l) 1.3  0.5 1.3  0.4 NS
TG (mmol/l) 2.0  1.1 1.9  1.0 NS
Diabetic treatment
Insulin 14/40 (35%) 10/35 (29%) NS
Diet therapy 6/40 (15%) 3/35 (9%) NS
Metformin 12/40 (30%) 16/35 (46%) NS
Sulphonylureas 22/40 (55%) 22/35 (63%) NS
Angiotensin-related drugs
ACE inhibitors 20/40 (50%) 17/35 (49%) NS
Spironolactone 4/40 (10%) 3/35 (9%) NS
Bonferroni adjustment was applied to account for all comparisons in the table.
ACE  angiotensin-converting enzyme; DH group  diabetic patients with left ventricular hypertrophy; DM group 
diabetic patients without left ventricular hypertrophy; HbA1c  hemoglobin A1c; HDL  high-density lipoprotein; LDL 
low-density lipoprotein; TG  triglycerides; NS  no significant difference.
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Figure 1. Relationship of strain and backscatter measurements in four groups. The top line shows a significant reduction of peak strain and strain rate in LVH (patients with left ventricular hypertrophy),
DM (diabetic patients with no LVH), and DH (diabetic patients with LVH) groups compared with CON (control) group. Peak strain and strain rate in the DH group were significantly less than those in
the DM and LVH group. The lower line shows septal calibrated integrated backscatter (IB) in the LVH, DM, and DH groups. Posterior wall calibrated IB in the LVH and DH groups were significantly
decreased compared with the CON group, without a significant difference in posterior wall calibrated IB between the DM and CON groups. There were no significant differences in calibrated IB of the septum
or posterior wall among the three patient groups. CI confidence interval; cIB calibrated integrated backscatter; PWcIB posterior wall calibrated integrated backscatter; ScIB septal calibrated integrated
backscatter.
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sensitive techniques. This study demonstrated that peak
strain and strain rate were significantly reduced in patients
with diabetes mellitus and that these changes were analo-
gous to those associated with LVH—which is recognized as
an important cause of myocardial dysfunction. Moreover,
the changes due to diabetes and LVH appear to be
synergistic, as evidenced by the significantly lower myocar-
dial contractility measured by peak strain and strain rate in
the DH group; these findings are consistent with those of
previous studies that show the combination of diabetes and
hypertension to have an adverse effect on the myocardium
(24). Left ventricular hypertrophy in the hearts of some
patients with diabetes may be mainly secondary to diabetes
rather than hypertension, supported by seven patients in the
DH group who had no history of hypertension.
Increase in myocardial reflectivity. Previous work has
shown positive associations between heart weight and total
fibrosis in patients with diabetes alone and with both
diabetes and LVH (24). Collagen is the primary determi-
nant of echocardiographic scattering in myocardial tissue
and there is quite good correlation between collagen depo-
sition and backscatter magnitude (29,30). The present study
showed calibrated IB was significantly increased in the three
patient groups, which confirms the previous findings
(24,31) and suggests that diabetes is as likely as LVH to be
associated with myocardial fibrosis, and this may be an
important factor in early diabetic heart disease. These
results are similar to those from a study that revealed greater
replacement of myocardium by fibrosis in rats with both
diabetes and hypertension than in rats with diabetes alone
(32).
Study limitations. Several limitations are inherent in this
observational study. Most patients were on medication, and
the average HbA1c was 7% to 8%, suggesting imperfect but
moderately successful control of blood sugar levels. A
greater spectrum of control might have facilitated elucida-
tion of the relationship between myocardial dysfunction and
glycemic control. Similarly, a greater spectrum of patients
might afford better insight into the relationship of dysfunc-
tion with duration of diabetes and also with medical
therapy. Finally, exclusion of an ischemic contribution was
mainly based on a normal result of dobutamine echocardi-
ography, although 13 patients had both normal dobutamine
echocardiography and coronary angiography. Clearly this
does not exclude the possibility of CAD because of the
possibility of false-negative results, but these are generally
associated with mild disease, and it seems unlikely that a
major ischemic contribution was present. This limitation is
unavoidable because it would be difficult to justify coronary
angiography in asymptomatic diabetic patients with normal
dobutamine echocardiograms on ethical grounds.
Clinical implications. The results of this study indicate
that myocardial structure (increased calibrated IB) and
function (decreased peak strain and strain rate) are altered
before the development of myocardial systolic dysfunction
in the hearts of patients with diabetes, and these alterations
potentially may be related to the subsequent development of
overt diabetic cardiomyopathy. Although similar to changes
caused by LVH, these changes are independent of LVH and
support a synergistic relationship between diabetes and
LVH as a cause of diabetic heart disease.
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